ML19277F184
| ML19277F184 | |
| Person / Time | |
|---|---|
| Site: | Limerick, 05000000, 05000447, Shoreham |
| Issue date: | 11/22/1983 |
| From: | Speis T Office of Nuclear Reactor Regulation |
| To: | Papazoglou I Brookhaven National Lab (BNL) |
| References | |
| CON-FIN-A-3725, CON-FIN-A-3740, FOIA-2023-000000184 NUDOCS 8312070417 | |
| Download: ML19277F184 (2) | |
Text
.
'NOV 2 2 7993 Mr. I. Papazoglou Brookhaven National Laboratory Building 130 Upton, NY 11973
Dear Dr. Papazoglcu:
In response to your letter of October 17, 1983, to A. Thadani concerning the impact of the GESSAR PRA review for external events on other RRAP programs, I would first like to indicate that I appreciate your promptness in bringing this to Mr. Thadani's attention. We have considered the impacts that you identified and offer the following guidance.
The guidance reflects our prioricies among these tasks along with updated schedules that we can meet our obligations.
We agree with your proposed revision to the Shoreham PRA review schedule, FIN A-3740.
This revised schedule for Shoreham will provide adequate relief for the Limerick PRA and SARA, FIN A-3725 in support of the Systems Interaction issue, and the GESSAR PRA review which remain high priority tasks.
Dr. Papazoglou and members of my staff have discussed GESSAR milestone changes such as a delay in the final NUREG/CR on internal events (Vol ;) from 1/30/84 to 2/15/84 and the draft NUREG/CR on external events (Vol 3) from 3/01/84 to 3/15/84.
The final NUREG/CR o' the integrated risk assessment (Vol 5) has been accelerated from 5/01/84 to 4/16/t1. We are still awaiting ycur revised submittal of Form 189 regarding the review of the GESSAR II PRA.
We appreciate your responsiveness in these matters.
Sincerely, Original Signed by 9312070417 831122 CF ADOCK 05000322 CF Fran k k7ece Themis P. Speis, Director
'g( Division of Safety Technology
Enclosure:
Distribution GESSAR PRA Review Schedule Central file @
% D/T Rdg A
RRAB Rdg TSpeis cc:
R. Bari FCoffman DST CHRON F. Rowsome Coffman CHRON A. Thadani RFrahm AThadani
- SEE PREVIOUS CONCURRENCE p
psome g omes) RRAB: DST RRAB: DST RRAB:DSTN AD/f:6$T D: DST
- g..g..g...g.
- g.........AThsdjhi"'~ ~ "FRdW6me""'
"TSpeit"*""
g
' " ' " " ' " " ^,
SURNAMt)
.....g.. gg..
.. g../.
"f83" "T..-./ ""783 "TT7%f783"'
oara y NRC f onM 318 10 80 NRCM 4
~
Mr. I. Papazo lou Brookhaven Nat} nal Laboratory
. Building 130 Upton, NY 11973
Dear Dr. Papazoglou:
In response to your le er of October 17, 1983, to A. Thadani concerning the impact of i.he GESSAR PRA review for external events on other RRAB programs, I would first like to indichte that I appreciate your promptness in bringing this to Mr. Thadani's atten(. ion.
We have considered the impacts that you identified anu cffar the foi owing guidance.
The guidance reflects our priorities among these tasks long with updated schedules that we can meet our obligations.
We agree with your proposed revis ~on to the Shoreham PRA review schedule, FIN A-3740.
This revised schedule or Shoreham will provide adequate relief for the Limerick PRA and SARA, FIN 3725 in support of the Systems Interaction issue, and the GESSAR PRA review which remain high priority tasks.
Dr. Papazoglou and members of my staff ha e discussed GESSAR milestone changes such as a delay in the final NUREG/CR on i ternal events (Val 1) from 1/30/84 to 2/15/84 and the draft NUREG/CR on external gents (Vol 3) from 3/01/84 to 3/15/84.
The final NUREG/CR on the integrated risk assissment (Vol 5) has been accelerated from 5/01/84 to 4/16/84.
We are still awaitinh your forrual submittal of Form 189 regarding the review of the GESSAR II PRA.
We appreciate your responsiveness in these matters.
Sincerely, Themis P. Speis, Directo Division of Safety Techno - gy
Enclosure:
GESSAR PRA Review Schedule Distribution Central file FRowsomt cc:
R. Bari RRAB Rdg AD/T Rdg F. Rowsome FCoffman Speis A. Thadani Coffman CHRON ST Chron RFrahm AThadani RRAB:DSTs/f/ RRAB: DST RRAB: DST AD/T: DST D: DST s
' RFEaid..........
.'MhhilihT' '..ibws3Ee' "
TSpEis'.."."... ' ".... '. '... ".. "
'. '.. ~. ~
a 1
su
>.F....o 1.1/../...f..../. 8. 3 11
......//..)..'..../. 8 3..1.1/......../. 8 311/....../. 83....
11../......./. 8. 3
,, n >
N40 f ORM 317 (1040) NRCV DNQ e
m ' 7,'
y, j
BROOKHAVEN NATIONAL LABORATORY
- r'l; ASSOCIATED UNIVERSITIES, INC.
L s1J J Upton. Long Island. New York 11973 (516) 282s Department of Nuclear Energy F1S 666' October 17, 1983 Dr. Ashok C. Thadani Reliability and Risk Assessment Branch Division of Safety Technology Office of Nuclear Reactor Regulation U. S. Nuclear Regulatory Commission Washington, D.C.
20555
Dear Ashok:
The purpose of this letter is to inform you of the impact that the involvement of Risk Evaluation Group (REG) personnel in the review of the GESSAR PRA f or " external events" will have on the milestones of other RRAB projects.
Presently, we anticipate per lorming a review of the " external events" GESSAR PPA of the same scope and level of ef ort as the one for the Limerick
' SARA (Project 3, FIN A-3393).
The GESSAR review will involve members of the REG for " system analysis", an outside consultant for the seismic hazard and fragility analysis, and members of the Reliability and Physical Analysis Group (headed by Dr. John Boccio) for the fire physical analysis part of the review.
A detailed schedule for the GESSAR review has not yet been established.
We anticipate, however, that between November 1,1983 and March 30, 1984, the review will require the equivalent of two months of Dr. Kelvin Shiu's time and two months of Dr. Nelson Hanan's time. They were the leading reviewers of the GESSAR " internal events" PRA.
Dr. Shiu is presently the leading reviewer of the Shoreham PRA and Dr.
Hanan is one of the key members of the " System Interactions" team.
Owing to Dr. Shiu's involvement with the GESSAR external event PRA, the milestones of the Shoreham PRA review (FIN A-3740) will change as follows:
FIN A-3740 Milestones Presently Stated in 189 New Task 1: Draft report on the review 3/15/84 4/30/84 Task 2:
Q-1 to applicant 10/31/83 11/30/83 Task 3:
Final report Two months after Unchanged receiving appropriate NRC comments 0Nk d'5 f hY
7 Dr. Hanan's involvement might affect some of the system interacticr.
milestones but the exact nature of the effect can not De determined prior to establishing a firm schedule for the GESSAR review.
An additional factor that might affect the Shoreham PRA review is the potential participation and/or contribution of Dr. Shiu to the Limerick hearings.
I would appreciate it if you could inform us about RRAB's plant concerning the nature and timing of BNL involvement to the aforementioned hearings.
I look forward to receiving your response tn these comments.
Best regards, D
- 1. A. Papazoglou, Group Leader Risk Evaluation Group IAP/cm cc:
A. Busiik (NRC]
Yuedixxc;;
J*~Wo# TiRC),]
T.
W. Kato R. Bari R. Hall J. Boccio
.